ハトウ　タイ   HATO Tai   羽藤　泰    所属   埼玉医科大学  医学部 総合医療センター　呼吸器外科    職種   准教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
掲載誌名	正式名：Clinical cancer research : an official journal of the American Association for Cancer Research 略　 称：Clin Cancer Res
掲載区分	国外
巻・号・頁	1(25),80-89頁
著者・共著者	Goyal Lipika, Zheng Hui, Abrams Thomas A, Miksad Rebecca, Bullock Andrea J, Allen Jill N, Yurgelun Matthew B, Clark Jeffrey W, Kambadakone Avinash, Muzikansky Alona, Knowles Michelle, Galway Aralee, Afflitto Anthony J, Dinicola Caroline F, Regan Eileen, Hato Tai, Mamessier Emilie, Shigeta Kohei, Jain Rakesh K, Duda Dan G, Zhu Andrew X
発行年月	2019/01
概要	Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS) of 10.7 months with sorafenib. FOLFOX4 has shown modest activity in advanced HCC. We evaluated the combination of sorafenib and modified (m)FOLFOX in a single-arm, multicenter phase II study.Sorafenib + mFOLFOX met the prespecified endpoint with encouraging efficacy but moderate hepatotoxicity. Thus, this regimen may be effective in select patients with adequate liver reserve. Biomarker evaluations suggested a correlation between time-to-progression (TTP) and angiogenic biomarkers and circulating Tregs.
DOI	10.1158/1078-0432.CCR-18-0847
PMID	30190369